The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://barbaravivk445431.nytechwiki.com/11029530/retatrutide_vs_tirzepatide_a_comparative_analysis